Isothiocyanates
Identity and Chemical Nature
In organic chemistry, isothiocyanate is a functional group found in compounds with the formula R−N=C=S. The isothiocyanate group is –NCS, formed by substituting sulfur for oxygen in the isocyanate group. Isothiocyanates are the more common isomers of thiocyanates, which have the formula R−S−C≡N. As a class, they are collectively abbreviated ITCs in the scientific literature. The defining feature shared across all members of this chemical family is the electrophilic –N=C=S moiety, which confers high reactivity with biological nucleophiles such as thiols and amines — a property central to essentially all known mechanisms of action.
Isothiocyanates are sulfur-containing phytochemicals with the general formula R-NCS naturally occurring as glucosinolate conjugates in cruciferous vegetables such as broccoli, cauliflower, kale, turnips, collards, Brussels sprouts, cabbage, radish, turnip, and watercress. Many isothiocyanates from plants are produced by enzymatic conversion of metabolites called glucosinolates.
The family encompasses a large number of structurally distinct members. The most intensively researched include:
- Sulforaphane (SFN) — derived from glucoraphanin, found at high levels in broccoli and broccoli sprouts.
- Allyl isothiocyanate (AITC) — a natural compound found in cruciferous vegetables such as horseradish, mustard, radish, and wasabi.
- Phenethyl isothiocyanate (PEITC) — found notably in watercress.
- Benzyl isothiocyanate (BITC) — found in garden cress and other Brassica species.
- Erucin, iberin, and indole-3-carbinol precursor glucosinolates — present across a broad range of Brassicaceae species.
Botanical Sources
Isothiocyanates are predominantly produced by plants in the Brassicaceae family, which includes broccoli, Brussels sprouts, kale, and other cruciferous vegetables. These foods are abundantly rich in ITCs and serve as vital components of a health-promoting diet. Broccoli, Brussels sprouts, kale, cabbage, cauliflower, mustard greens, and radishes are among the richest dietary sources.
Broccoli and its sprouts are particularly noted for high levels of sulforaphane, a well-studied isothiocyanate. Broccoli sprouts — three-day-old seedlings of Brassica oleracea var. italica — are recognized as among the most concentrated dietary sources of glucoraphanin, the sulforaphane precursor. PEITC is derived from the hydrolysis of its glucosinolate precursor gluconasturtiin. In humans, consumption of dietary glucosinolates is estimated to be about 300 mg/day from various cruciferous vegetables, and for every 56.8 g of watercress consumed, approximately 12 mg of PEITC is released.
Other non-Brassicaceae sources, such as capers (Capparis spinosa), moringa (Moringa oleifera), and papaya seeds (Carica papaya), also contain glucosinolates. Moringa oleifera has emerged as a distinctive source of isothiocyanates, notably 4-(α-L-rhamnopyranosyloxy)-benzyl isothiocyanate (moringin), which includes an uncommon rhamnose sugar moiety. This structural feature is rare among ITCs and plays a key role in enhancing the compound's solubility, metabolic stability, and bioavailability.
Common Forms and Preparations
Isothiocyanates are obtained primarily through dietary consumption of whole cruciferous vegetables, but they are also available in concentrated supplement forms. Dietary supplements containing extracts of broccoli sprouts, broccoli, and other cruciferous vegetables are available without a prescription, and some products are standardized to contain a minimum amount of glucosinolates and/or sulforaphane. In the United States, both broccoli and watercress are available in the form of dietary supplement capsules.
The bioavailability of isothiocyanates was found to be much lower with the consumption of broccoli supplements devoid of myrosinase than with the consumption of fresh broccoli sprouts. Peak concentrations of sulforaphane metabolites were found to be eight- and five-times greater in plasma and urine, respectively, following fresh broccoli versus supplement consumption. This disparity reflects the fact that ITCs are not preformed in intact plant tissue — they require enzymatic release at the moment of tissue disruption.
Cooking method significantly affects ITC yield. Cooking significantly alters the isothiocyanate yields, showing an average four-fold increase by lightly cooking (stir-frying, steaming, and microwaving) and a 58% decrease by heavily cooking (boiling). Heavy boiling inactivates plant myrosinase and leaches glucosinolates into cooking water, substantially reducing ITC yield.
Traditional and Historical Use
The plants richest in isothiocyanates — horseradish, mustard, watercress, and cabbage — have been employed medicinally and culinarily for thousands of years, long before the chemistry responsible for their effects was understood. The isothiocyanates themselves were not identified as distinct chemical entities until the nineteenth century, but the pungent compounds in these plants were well recognized by ancient cultures.
Ancient and Classical Antiquity
The Egyptians knew and used horseradish as early as 1500 BC. At the time of the Jewish Exodus, horseradish was designated as one of the "five bitter herbs" that the Jews were told to eat during Passover. The early Greeks used horseradish as a lower back rub and an aphrodisiac. According to Greek mythology, the Delphic Oracle told Apollo that the horseradish was worth its weight in gold.
Horseradish has been cultivated and used as a medicine and condiment for at least 2,000 years. The Greeks used it as both a seasoning in their favorite recipes and a medicinal plant, praising its supposed benefits for everything from back pain to digestive issues.
Medieval and Early Modern Europe
Both the root and leaves of horseradish were universally used as a medicine during the Middle Ages, and as a condiment in Denmark and Germany. Both roots and leaves were used as a traditional medicine during the Middle Ages. The root was used as a condiment on meats in Germany, Scandinavia, and Britain.
Medicinal actions attributed to horseradish included those of a stimulant, aperient, rubefacient, diuretic, and antiseptic. It was regarded as a powerful stimulant whether applied internally or externally. Taken with oily fish or rich meat, it was used to stimulate the digestive organs. It was also used as a strong diuretic by herbalists in cases of calculus and related conditions.
The herbalist John Gerard described horseradish in 1597 under the name Raphanus rusticanus, noting its medicinal uses and its growing (but still unfamiliar to English readers) role as a condiment among Germans. William Turner mentions horseradish as Red Cole in his Herbal (1551–1568), but not as a condiment.
By the period 1300–1600, the root was being used by Europeans — especially in Central Europe, Scandinavia, and England — for medicinal purposes such as cough expectorant and treatment for food poisoning, scurvy, tuberculosis, and colic.
North America and Other Traditions
Horseradish was introduced to North America during European colonization; both George Washington and Thomas Jefferson mention it in garden accounts. Native Americans used it to stimulate the glands, stave off scurvy, and as a diaphoretic treatment for the common cold.
Traditional medicine systems, especially in Asia, have used mustard and related plants for digestive and respiratory health, indirectly supporting the inclusion of ITC-rich foods in the diet.
Chemical History
Allyl isothiocyanate first appeared in the chemical literature in three 1890s articles about isothiocyanates by Augustus E. Dixon at Queen's College, Galway. At the time, AITC was called "allylthiocarbimide." It was not until 1964 that AITC appeared in a biological study, when Misao Kojima at Fukuoka University identified it in dried wasabi (Wasabia japonica) roots. Systematic scientific interest in ITCs as cancer-chemopreventive agents did not begin until the early 1990s.
Biosynthesis: From Glucosinolates to Isothiocyanates
In cruciferous plants, glucosinolates are formed from amino acids. These sulfur-containing secondary metabolites are stored separately from the enzyme responsible for their breakdown. Isothiocyanates are stored as glucosinolates in cruciferous vegetables. In plants, glucosinolates coexist with but are physically segregated from an endogenous enzyme myrosinase (thioglucoside glucohydrolase, EC 3.2.1.1).
The conversion of glucosinolates to isothiocyanates is a crucial enzymatic process involving myrosinase, a thioglucosidase enzyme. When plant cells are damaged, myrosinase comes into contact with glucosinolates, hydrolyzing them to produce unstable aglycones, which spontaneously rearrange to form isothiocyanates. This conversion is not only essential for the plant's defense against herbivores and pathogens but also significant for the health benefits observed in humans consuming these plants.
The hydrolysis leads to the formation of an unstable aglycone intermediate (thiohydroxamate-O-sulfonate), glucose, and sulfate. This aglycone undergoes a spontaneous non-enzymatic Lossen rearrangement to yield isothiocyanates, thiocyanates, nitriles, oxazolidinethiones, and epithionitriles, depending on the structure of the glucosinolate and the chemical conditions, such as pH, availability of ferrous ions, and the presence of myrosinase-interacting proteins.
At neutral pH, the primary product is the isothiocyanate. Under acidic conditions (pH <3) and in the presence of ferrous ions or epithiospecifier proteins, the formation of nitriles is favored instead.
Tissue disruption by chewing starts the breakdown of glucosinolates into isothiocyanates, and this provides protection from plants towards insects, as isothiocyanates are pungent metabolites. The most potent of such defense products are isothiocyanates, followed by thiocyanates and nitriles.
When cruciferous vegetables are cooked before consumption, plant myrosinase is inactivated by heat; however, a large proportion of intact glucosinolates reaches the colon. In the colon, myrosinase produced by the microbiota can catalyze the generation of a wide range of metabolites from glucosinolates, depending on the pH and the presence of cofactors. The hydrolysis of glucosinolates at neutral pH results in the formation of unique isothiocyanates.
Key Active Compounds and Established Mechanisms of Action
Phase II Enzyme Induction and the Keap1–Nrf2–ARE Pathway
The most robustly characterized mechanism of isothiocyanates is induction of the Nrf2 (nuclear factor erythroid 2-related factor 2) transcription factor pathway. Sulforaphane activates Nrf2, a basic leucine zipper transcription factor that serves as a defense mechanism against oxidative stress and electrophilic toxicants by inducing more than a hundred cytoprotective proteins, including antioxidants and phase II detoxifying enzymes.
Isothiocyanates appear to alter gene expression through modification of critical thiols in regulatory proteins such as Keap1 (Kelch-like ECH-associated protein 1) or IKK (IκB kinase), causing activation of Nrf2 and related pathways. In normal cellular conditions, Keap1 sequesters Nrf2 in the cytoplasm and targets it for proteasomal degradation. The electrophilic –N=C=S group of ITCs chemically modifies cysteine residues on Keap1, disrupting this interaction, freeing Nrf2 to translocate to the nucleus and bind antioxidant response elements (ARE) in target gene promoters.
Animal and human studies have shown induction of numerous Phase II enzymes via the Nrf2 pathway, including superoxide dismutase, catalase, NAD(P)H:quinone oxidoreductase 1, glutathione peroxidase, glutathione reductase, and glutathione-S-transferase.
Inhibition of Phase I Enzymes (CYP Enzymes)
Isothiocyanates such as phenethyl isothiocyanate and sulforaphane have been shown to inhibit carcinogenesis through inhibition of cytochrome P450 enzymes. This phase I enzyme inhibition reduces the metabolic activation of procarcinogens to ultimate carcinogens, representing an upstream chemopreventive mechanism distinct from the phase II induction pathway.
NF-κB Inhibition and Anti-Inflammatory Signaling
Isothiocyanates have the ability to repress NF-κB (nuclear factor-κB) activity, inhibit histone deacetylase, and inhibit cytochrome P450. Sulforaphane downregulates the expression of pro-inflammatory cytokines, chemokines, adhesion molecules, cyclooxygenase-2, and inducible nitric oxide synthase.
Isothiocyanates have been reported to counteract the pathogenesis of endothelial dysfunction, including upregulation of Nrf2-dependent antioxidant response elements (HO-1, GCLC, and GCLM) and downregulation of adhesion molecules (ICAM-1, VCAM-1, and E-selectin) via inhibition of NF-κB activation.
Apoptosis, Cell Cycle Arrest, and Pro-Oxidant Effects
ITCs suppress tumor growth by generating reactive oxygen species or by inducing cell cycle arrest leading to apoptosis. Sulforaphane is by far the most studied antioxidant ITC, acting primarily through the induction of Nrf2. Paradoxically, sulforaphane, as a pro-oxidant compound, can also increase the levels of reactive oxygen species, a mechanism attributed to its anticancer effect.
The major molecular signaling pathways for the anticancer activities of PEITC include: (1) activation of apoptosis pathways; (2) induction of cell cycle arrest; and (3) inhibition of survival pathways.
Epigenetic Regulation
Isothiocyanates have the ability to inhibit histone deacetylase (HDAC). Inhibition of HDACs promotes a more permissive chromatin configuration at tumor suppressor gene promoters, potentially restoring normal gene expression patterns that are silenced in cancer cells. Total HDAC activity in peripheral blood mononuclear cells of broccoli sprout consumers was reported to be significantly lower than in PBMCs of subjects who consumed broccoli supplements devoid of active myrosinase.
Mercapturic Acid Pathway Metabolism
Absorbed isothiocyanates are rapidly conjugated to glutathione in the liver, and then sequentially metabolized in the mercapturic acid pathway before being excreted in the urine. Using sulforaphane as the model isothiocyanate, it has been established that its metabolites — sulforaphane-glutathione, sulforaphane-cysteine-glycine, sulforaphane-cysteine, and sulforaphane N-acetylcysteine — collectively known as dithiocarbamates, are ultimately excreted in the urine. These dithiocarbamate metabolites serve as quantifiable urinary biomarkers of ITC exposure in human studies.
Scientific Evidence by Area of Use
Cancer Chemoprevention
Epidemiological evidence: Most meta-analyses found inverse associations between cruciferous vegetable intake and risk of bladder, breast, colorectal, endometrial, gastric, lung, ovarian, pancreatic, prostate, and renal cancer. However, subgroup analyses showed that inverse associations remained significant in pooled analyses of case-control studies but not in pooled analyses of prospective cohort studies. Retrospective case-control studies are susceptible to selection and dietary recall bias compared to prospective cohort studies.
Preclinical evidence: Naturally occurring isothiocyanates and their metabolites have been found to inhibit the development of chemically-induced cancers of the lung and other organ sites in rodent models. With the shared active –NCS structure, these compounds have shown multifaceted chemopreventive activities against cancer, including modulation of phase I and phase II enzymes to block carcinogenesis, and induction of apoptosis and cell cycle progression to inhibit growth of malignant cells.
Clinical/human evidence: Based on the outcomes of pre-clinical studies, few ITCs have advanced to the clinical phase. The clinical picture remains early-stage:
- A Phase I clinical trial (NCI CN-55120) reported that 10 μM PEITC can be achieved in the plasma after intake of 200 mg PEITC orally in human volunteers.
- PEITC is one of the most comprehensively studied ITCs in various cancers and is currently being evaluated in a National Cancer Institute Phase II clinical trial to prevent lung cancer in smokers.
- A presurgical-window intervention trial of isothiocyanate-rich broccoli sprout extract in patients with breast cancer was conducted (Wang et al., 2022, Mol Nutr Food Res), examining direct tumor-tissue effects.
Evidence strength: Despite convincing preclinical evidence, the progress toward clinical translation for ITCs has been rather disappointing, probably due to a variety of reasons, including lack of suitably formulated agents for oral administration, regulatory issues, and complexities associated with primary prevention clinical trials requiring thousands of subjects and years of follow-up. The epidemiological associations are suggestive but are inconsistent between study designs, and direct clinical evidence of cancer prevention in humans remains limited and preliminary.
Cardiovascular Health
Sulforaphane is an ITC shown to possess anticancer activities by both in vivo and epidemiological studies. Recent data have indicated that the beneficial effects of SFN in cardiovascular disease (CVD) are due to its antioxidant and anti-inflammatory properties. Isothiocyanates protect against oxidized LDL-induced endothelial dysfunction by upregulating Nrf2-dependent antioxidation and suppressing NF-κB activation.
Although promising effects on blood pressure, lipid profiles, and glycaemic control have been observed, clinical studies are often limited by small sample sizes, study heterogeneity, and high inter-individual variability, particularly related to gut microbiota and host metabolic phenotype. The cardiovascular evidence base in humans remains preliminary; most supporting data come from in vitro models and animal studies.
A small pilot study (Steenwijk et al., described in a 2025 editorial in Frontiers in Nutrition) involving 12 subjects found that when a single oral intake of sulforaphane in the form of broccoli sprouts (16 g) was followed by a high-calorie challenge, platelet responsiveness and improved functionality were observed. This was a preliminary, small intervention study and requires replication at greater scale.
Metabolic Disorders and Diabetes
Activation of Nrf2, including its associated cytoprotective genes, is the predominant mechanism by which sulforaphane enhances cellular defense mechanisms, including improving redox status in experimental models of diabetes. Another prominent feature of Nrf2 activation by sulforaphane is inhibition of inflammation.
In a mouse model of streptozotocin-induced diabetes, sulforaphane improved renal performance and minimized pathological changes in the glomerulus. Motor nerve conduction velocity, blood flow, and pain behavior were also improved. These findings encourage the potential development of sulforaphane as a therapeutic to alleviate metabolic disorder and protect against renal damage and pain associated with diabetes.
A randomized, double-blind clinical trial demonstrated sulforaphane's ability to reduce oxidative stress in type 2 diabetes. Although promising effects on blood pressure, lipid profiles, and glycaemic control have been observed, clinical studies are often limited by small sample sizes, study heterogeneity, and high inter-individual variability. The human evidence for metabolic/diabetes applications is promising but currently insufficient to establish clinical recommendations.
Neurological and Neurodevelopmental Conditions
Similar to carcinogenesis and cardiovascular disease, oxidative stress and chronic inflammation are central to the pathogenesis of diseases of the central nervous system, and the protective effects of isothiocyanates are evident in models of nervous tissue injury and neurodegeneration.
Sulforaphane has been shown to protect neural mitochondria by activating Nrf2 and reduce neuroinflammation by inhibiting NF-κB.
In the area of autism spectrum disorder (ASD), neurodevelopmental and neurodegenerative conditions impacted by treatment with ITCs are subject of extensive review, with special scrutiny given to more than 80 preclinical studies and 16 clinical studies evaluating the effects of sulforaphane on autism spectrum disorder and schizophrenia. ASD was also the focus of an animal model and human clinical study following 12 weeks of sulforaphane supplementation (equivalent to 30 μmol). Changes in abundance of specific microbial taxa were associated with improvements in ASD symptoms following sulforaphane treatment in both rats and humans. These findings are considered preliminary and require larger, confirmatory trials.
Inflammation and Immune Modulation
The anti-inflammatory effects of allyl isothiocyanate are accompanied by an increase in Nrf2 nuclear translocation and consequently increased mRNA and protein levels of the Nrf2 target gene heme-oxygenase 1. AITC was slightly less potent than sulforaphane in down-regulating inflammation in LPS-stimulated macrophages. Data suggest that AITC exhibits potent anti-inflammatory activity in cultured macrophages in vitro but has only little anti-inflammatory activity in mice in vivo.
A pilot clinical study examined sulforaphane's effects in HIV: the first ever study of the effects of sulforaphane on human beings living with HIV, a 16-week pilot study of 14 virally suppressed HIV patients given 225 μmol SF daily, demonstrated a reduction in C-reactive protein. This study is small and preliminary but supports further investigation of ITCs in chronic inflammatory states.
Antimicrobial Properties
Recent research has provided data on the antimicrobial properties of allyl isothiocyanate in a Drosophila model system. This demonstrates concentration-dependent direct antimicrobial properties as well as the ability to modulate host production of antimicrobial peptides, adding to the body of evidence on allyl-ITC functionality. Sulforaphane has been reported to exhibit antimicrobial activity. Most antimicrobial evidence for ITCs remains at the in vitro or animal model stage; clinical evidence in humans is lacking.
Lung Cancer and Tobacco Carcinogen Detoxification
Phenethyl isothiocyanate and sulforaphane exhibit tumor preventive activity in lung, prostate, breast, and colon cancers in preclinical models. In the clinical realm, a notable early study used PEITC specifically to target tobacco carcinogen detoxification. PEITC is currently being evaluated in a National Cancer Institute Phase II clinical trial to prevent lung cancer in smokers. The compound has been extensively studied as a chemopreventive agent in several preclinical species and in humans.
Body Systems and Health Areas Associated with Isothiocyanates
Based on the accumulated evidence — ranging from cell culture through animal studies to early-phase human trials — isothiocyanates have been studied for effects on the following body systems:
- Oncology/Chemoprevention: Multiple cancer types including lung, breast, prostate, colon, bladder, and others — primarily through phase II enzyme induction, apoptosis, and HDAC inhibition.
- Cardiovascular system: Endothelial function, oxidized LDL metabolism, platelet activity — via Nrf2/NF-κB modulation.
- Metabolic system: Glycaemic control, renal protection in diabetes, lipid metabolism — primarily via Nrf2 and AMPK pathways.
- Central nervous system: Neuroprotection, neuroinflammation, autism spectrum disorder, schizophrenia — via Nrf2 activation and NF-κB suppression.
- Immune system: Modulation of cytokine production, macrophage activation, CRP reduction in chronic inflammatory states.
- Gastrointestinal system: Antimicrobial effects against Helicobacter pylori (notably in animal and limited human studies); gut microbiota modulation through glucosinolate metabolism.
- Thyroid: A matter of safety concern (see below) rather than therapeutic application.
Sulforaphane has been found to be a promising chemopreventive agent against not only a variety of cancers such as breast, prostate, colon, skin, lung, stomach, and bladder but also against cardiovascular and neurodegenerative diseases and diabetes.
Bioavailability and Pharmacokinetics
The bioavailability of ITCs is highly variable and depends on the form of consumption, degree of food processing, and individual gut microbiota composition. Glucosinolates and their breakdown products, isothiocyanates, are bioactive compounds with anti-inflammatory, antioxidant, and anticancer properties, mediated through key pathways such as Nrf2, NF-κB, and epigenetic regulation. However, their limited and variable bioavailability remains a key challenge.
Sulforaphane's high bioavailability profile is one of its advantages. In people in good general health, oral administration of 200 µmol broccoli sprout isothiocyanates resulted in a peak of 0.943–2.27 µmol/L of isothiocyanate in plasma one hour after ingestion.
In humans, chewing of Brussels sprouts releases 39% of the glucosinolates as isothiocyanates measured in the urine, whereas no chewing results in the excretion of 26% of isothiocyanates. This illustrates the importance of thorough mastication to activate the plant myrosinase system.
Appearance of sulforaphane metabolites in urine and plasma is delayed after consumption of dried broccoli powders compared to consumption of broccoli sprouts, likely due to the lack of active ingested myrosinase and dependence on the gut microbiome to supply it.
Pharmacokinetic features of PEITC include linear and first-order absorption, high protein binding and capacity-limited tissue distribution, and reversible metabolism and capacity-limited hepatic elimination. PEITC is metabolized by glutathione S-transferase in the liver, with the glutathione conjugate of PEITC undergoing further conversion to mercapturic acid by N-acetyl transferase in rats and humans.
Dosages Reported in Studies
The following dosages are reported directly from cited clinical and human studies and are presented descriptively:
- Twelve healthy human volunteers received doses of broccoli sprout preparations every 8 hours for 7 days (21 total doses). Doses used in three cohorts were 25 μmol glucosinolates, 100 μmol glucosinolates, and 25 μmol isothiocyanates, respectively — equivalent to receiving 75–300 μmol glucosinolates daily (approximately 12–50 g of fresh broccoli seeds) or 75 μmol isothiocyanate daily. No clinical adverse events were reported.
- In a Phase I clinical trial, 200 mg PEITC orally in human volunteers achieved 10 μM PEITC in plasma.
- In a 16-week pilot study in virally suppressed HIV patients, 225 μmol sulforaphane daily was administered, demonstrating a reduction in C-reactive protein.
- A 12-week sulforaphane supplementation study in autism spectrum disorder used a dose equivalent to 30 μmol.
- Based on reports in the literature, 450 μmol of sulforaphane as a beverage or soup exceeds a tolerable level for healthy individuals, and a maximum tolerated dose may be 200 μmol or lower.
- A maximal plasma concentration of approximately 1.0 μM is achieved by consumption of 100 grams of watercress.
- For every 56.8 g of watercress consumed, approximately 12 mg of PEITC is released.
Safety Considerations and Interactions
General Tolerability at Dietary Levels
There were no alterations in standard clinical chemistry tests (i.e., liver and kidney function) amongst pre- and post-intervention measures in studies of broccoli sprout preparations at typical doses. At doses achievable through ordinary dietary consumption of cruciferous vegetables, ITCs are generally regarded as well tolerated.
Gastrointestinal Effects
Some potential adverse effects of sulforaphane supplementation may include gastrointestinal discomforts, such as nausea, vomiting, and diarrhea. The isothiocyanates may irritate mucous membranes on contact or if inhaled. Ingestion of large amounts can cause bloody vomiting and diarrhea. These severe effects are associated with consumption of large quantities, not standard dietary intake.
Goitrogenic Concerns and Thyroid Function
Brassica vegetables are a rich source of sulfur compounds, such as glucosinolates and isothiocyanates, which provide health benefits but are also suspected of having a goitrogenic effect. An early study examined 32 types of hematology and chemistry tests, including thyroid function (TSH, T3, and T4) tests. Altered thyroid function is a potential concern occasionally raised in association with crucifer-based interventions, given the presence of low levels of goitrogens.
It is important to distinguish between sulforaphane specifically and goitrogenic compounds found in the same vegetables. Sulforaphane is not a goitrogen by itself; rather, it is derived from glucoraphanin, a glucosinolate. The goitrogenic effects are associated with other glucosinolate breakdown products such as goitrin (from gluconapin), not with sulforaphane or most ITCs. Some concerns have arisen that sulforaphane may disrupt thyroid hormone function and potentially act as a goitrogen by competing with iodine uptake. However, long-term studies in iodine-deficient or hypothyroid animals showed no ill effects with high dose sulforaphane supplementation.
Drug Interactions
Sulforaphane may interact with certain medications, such as blood thinners, increasing the risk of bleeding. Sulforaphane may lower blood glucose levels, so it could enhance the effects of medications used to treat diabetes, such as insulin and oral hypoglycemic agents.
Because ITCs modulate cytochrome P450 enzyme activity — both inducing phase II enzymes and inhibiting selected phase I CYPs — there is a theoretical basis for interactions with drugs that are substrates of these enzyme systems. The clinical significance of these interactions at dietary levels of ITC intake has not been definitively established in human studies.
High-Dose Toxicity
Previous studies have reported toxicity occurring at higher doses of sulforaphane in rats, which underscores the need for careful attention to risk-benefit analyses and the determination of therapeutic doses. It was noted that high doses of SFN injected intraperitoneally into rats led to significant side effects, including marked sedation (at 150–300 mg/kg), hypothermia (at 150–300 mg/kg), disturbed motor coordination (at 200–300 mg/kg), decreased skeletal muscle strength (at 250–300 mg/kg), and death (at 200–300 mg/kg). These findings highlight the need for responsible dosing strategies. These data come from parenteral administration in animals and are not directly extrapolable to oral human doses.
Pregnancy and Vulnerable Populations
Sulforaphane has also been found to have goitrogenic effects, which can interfere with thyroid function and may exacerbate thyroid disorders in some individuals. Moreover, the safety of sulforaphane supplements during pregnancy and breastfeeding is not well established. Data on sulforaphane use in children or elderly populations are sparse.
Genetic Variation: GST Polymorphisms
Whether potential protection conferred by isothiocyanates via the Nrf2-dependent pathway is diminished in individuals carrying GST null variants is currently unknown. Some, but not all, observational studies have suggested that GST genotypes could influence the associations between cruciferous vegetable consumption and risk of disease. Individuals homozygous null for GSTM1 and/or GSTT1 — common polymorphisms — may metabolize ITCs differently, potentially altering both efficacy and accumulation.
Summary of Evidence Strength
The scientific literature on isothiocyanates is extensive at the preclinical level, with a substantial mechanistic understanding established through in vitro and animal research. Human evidence, while growing, is characterized by the following limitations: clinical studies are often limited by small sample sizes, study heterogeneity, and high inter-individual variability, particularly related to gut microbiota and host metabolic phenotype. For cancer chemoprevention specifically, the progress toward clinical translation has been rather disappointing, with primary prevention trials requiring thousands of subjects and years of follow-up to draw meaningful conclusions. The field continues to generate new clinical trials, particularly for sulforaphane (the best-studied ITC), but definitive evidence of clinical benefit in humans remains to be established for most applications.
References
Go back